Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children.

IF 2.5 4区医学 Q3 INFECTIOUS DISEASES

Journal of the Pediatric Infectious Diseases Society Pub Date : 2025-01-23 DOI:10.1093/jpids/piaf004

Christine R Lockowitz, Alice J Hsu, Kathleen Chiotos, Laura L Bio, Aimee M Dassner, Andrew B Gainey, Jennifer E Girotto, Denise Iacono, Taylor Morrisette, Grant Stimes, M Tuan Tran, William S Wilson, Pranita D Tamma

{"title":"Suggested Dosing of Select Beta-lactam Agents for the Treatment of Antimicrobial-Resistant Gram-Negative Infections in Children.","authors":"Christine R Lockowitz, Alice J Hsu, Kathleen Chiotos, Laura L Bio, Aimee M Dassner, Andrew B Gainey, Jennifer E Girotto, Denise Iacono, Taylor Morrisette, Grant Stimes, M Tuan Tran, William S Wilson, Pranita D Tamma","doi":"10.1093/jpids/piaf004","DOIUrl":null,"url":null,"abstract":"Background: The Infectious Diseases Society of America (IDSA) publishes annual guidance on the treatment of antimicrobial-resistant (AMR) gram-negative infections. Within the AMR guidance, suggested dosages of antibiotics for adults infected with AMR pathogens are provided. This document serves as a companion document to the IDSA guidance to assist pediatric specialists with dosing β-lactam agents for the treatment of AMR infections in children.Methods: A panel of 13 pediatric infectious diseases specialists, including 11 pharmacists and two physicians, reviewed existing pharmacokinetic/pharmacodynamic, animal, and clinical data for newer β-lactam agents that are available in the United States and suggested for the treatment of AMR infections (i.e., cefiderocol, ceftazidime-avibactam, ceftazidime-avibactam & aztreonam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, sulbactam-durlobactam). Suggested dosing for ampicillin-sulbactam is also provided given complexities in appropriate dosing for carbapenem-resistant Acinetobacter baumannii infections.Results: Consensus-based suggested dosing for β-lactam agents used to treat AMR infections in neonates, infants, children, and adolescents and relevant supporting evidence are provided. Content is up to date as of December 1st, 2024. Gaps and limitations to existing data are discussed.Conclusion: Optimizing antibiotic dosing is critical to improving the outcomes of children with AMR infections.","PeriodicalId":17374,"journal":{"name":"Journal of the Pediatric Infectious Diseases Society","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pediatric Infectious Diseases Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpids/piaf004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The Infectious Diseases Society of America (IDSA) publishes annual guidance on the treatment of antimicrobial-resistant (AMR) gram-negative infections. Within the AMR guidance, suggested dosages of antibiotics for adults infected with AMR pathogens are provided. This document serves as a companion document to the IDSA guidance to assist pediatric specialists with dosing β-lactam agents for the treatment of AMR infections in children.

Methods: A panel of 13 pediatric infectious diseases specialists, including 11 pharmacists and two physicians, reviewed existing pharmacokinetic/pharmacodynamic, animal, and clinical data for newer β-lactam agents that are available in the United States and suggested for the treatment of AMR infections (i.e., cefiderocol, ceftazidime-avibactam, ceftazidime-avibactam & aztreonam, ceftolozane-tazobactam, imipenem-cilastatin-relebactam, meropenem-vaborbactam, sulbactam-durlobactam). Suggested dosing for ampicillin-sulbactam is also provided given complexities in appropriate dosing for carbapenem-resistant Acinetobacter baumannii infections.

Results: Consensus-based suggested dosing for β-lactam agents used to treat AMR infections in neonates, infants, children, and adolescents and relevant supporting evidence are provided. Content is up to date as of December 1st, 2024. Gaps and limitations to existing data are discussed.

Conclusion: Optimizing antibiotic dosing is critical to improving the outcomes of children with AMR infections.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Pediatric Infectious Diseases Society Medicine-Pediatrics, Perinatology and Child Health

CiteScore

6.70

自引率

0.00%

发文量

179

期刊介绍： The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases. The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.